The high-intensity staining in a large proportion of these tumor samples (71.4% for HDAC1 and 92.9% for HDAC2, Figure 2E) suggests that HDACs are also relevant in the context of cisplatin-resistant phenotype, thus indicating that targeting with HDACis may be an effective therapy. This evidence concerns the gene HDAC2 and neoplasm.